Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) — Working Capital to Net Assets Ratio
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a Working Capital to Net Assets ratio of 119.1% as of September 2025. Working capital of $976.37 Million (current assets of $1.84 Billion minus current liabilities of $862.11 Million) is measured against net assets of $819.93 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Amneal Pharmaceuticals, Inc. Class A Com (AMRX) financial flexibility to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Amneal Pharmaceuticals, Inc. Class A Common Stock Working Capital to Net Assets (2015–2024)
This chart shows how Amneal Pharmaceuticals, Inc. Class A Common Stock's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2015 to 2024. As of September 2025, the ratio stands at 119.1%, reflecting working capital of $976.37 Million against net assets of $819.93 Million USD. See Amneal Pharmaceuticals, Inc. Class A Com liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2024, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Amneal Pharmaceuticals, Inc. Class A Com market capitalisation.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -1028.4% | $458.04 Million | $-44.54 Million | $1.59 Billion | $1.13 Billion | ▼ -3683.3 pp |
| 2023 | 2654.9% | $531.27 Million | $20.01 Million | $1.38 Billion | $846.60 Million | ▲ +2339.5 pp |
| 2022 | 315.4% | $659.02 Million | $208.93 Million | $1.41 Billion | $752.80 Million | ▲ +85.7 pp |
| 2021 | 229.7% | $842.87 Million | $366.97 Million | $1.52 Billion | $677.24 Million | ▼ -23.9 pp |
| 2020 | 253.6% | $874.64 Million | $344.93 Million | $1.55 Billion | $676.90 Million | ▲ +63.3 pp |
| 2019 | 190.3% | $659.80 Million | $346.79 Million | $1.21 Billion | $550.41 Million | ▲ +108.5 pp |
| 2018 | 81.8% | $732.79 Million | $896.36 Million | $1.29 Billion | $553.85 Million | ▲ +208.2 pp |
| 2017 | -126.5% | $475.05 Million | $-375.58 Million | $771.93 Million | $296.88 Million | ▲ +158.3 pp |
| 2016 | -284.8% | $501.04 Million | $-175.94 Million | $726.11 Million | $225.07 Million | ▼ -89.2 pp |
| 2015 | -195.6% | $365.45 Million | $-186.87 Million | $604.60 Million | $239.15 Million | — |